Authors
MK Wilson, E Pujade-Lauraine, D Aoki, MR Mirza, D Lorusso, AM Oza, A du Bois, I Vergote, A Reuss, M Bacon, M Friedlander, D Gallardo-Rincon, F Joly, S-J Chang, AM Ferrero, RJ Edmondson, P Wimberger, J Maenpaa, D Gaffney, R Zang, A Okamoto, G Stuart, K Ochiai
Publication date
2017/4/1
Source
Annals of Oncology
Volume
28
Issue
4
Pages
727-732
Publisher
Elsevier
Description
This manuscript reports the consensus statements regarding recurrent ovarian cancer (ROC), reached at the fifth Ovarian Cancer Consensus Conference (OCCC), which was held in Tokyo, Japan, in November 2015. Three important questions were identified: (i) What are the subgroups for clinical trials in ROC? The historical definition of using platinum-free interval (PFI) to categorise patients as having platinum-sensitive/resistant disease was replaced by therapy-free interval (TFI). TFI can be broken down into TFIp (PFI), TFInp (non-PFI) and TFIb (biological agent-free interval). Additional criteria to consider include histology, BRCA mutation status, number/type of previous therapies, outcome of prior surgery and patient reported symptoms. (ii) What are the control arms for clinical trials in ROC? When platinum is considered the best option, the control arm should be a platinum-based therapy with or without an anti …
Scholar articles
MK Wilson, E Pujade-Lauraine, D Aoki, MR Mirza… - Annals of Oncology, 2017